Literature DB >> 7981013

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms.

T Andersson1, J O Miners, M E Veronese, D J Birkett.   

Abstract

1. The primary metabolism of diazepam was studied in human liver microsomes in order to investigate the kinetics and to identify the cytochrome P450 (CYP) isoforms responsible for the formation of the main diazepam metabolites, temazepam and N-desmethyldiazepam. 2. The formation kinetics of both metabolites were atypical and consistent with the occurrence of substrate activation. A sigmoid Vmax model equivalent to the Hill equation was used to fit the data. The degree of sigmoidicity was greater for temazepam formation than for N-desmethyldiazepam formation, so that the ratio of desmethyldiazepam:temazepam formation increased as the substrate (diazepam) concentration decreased. 3. alpha-Naphthoflavone activated both reactions but with a greater effect on temazepam formation than on N-desmethyldiazepam formation. In the presence of 25 microM alpha-naphthoflavone the kinetics for both pathways were approximated by Michaelis-Menten kinetics. 4. Studies with a series of CYP isoform selective inhibitors and with an inhibitory anti-CYP2C antibody indicated that temazepam formation was carried out mainly by CYP3A isoforms, whereas the formation of N-desmethyldiazepam was mediated by both CYP3A isoforms and S-mephenytoin hydroxylase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7981013      PMCID: PMC1364858          DOI: 10.1111/j.1365-2125.1994.tb04336.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

Authors:  T Andersson; C Cederberg; G Edvardsson; A Heggelund; P Lundborg
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

2.  Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone.

Authors:  G E Schwab; J L Raucy; E F Johnson
Journal:  Mol Pharmacol       Date:  1988-05       Impact factor: 4.436

3.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

Review 4.  Factors influencing the metabolism of diazepam.

Authors:  L Bertilsson; T A Baillie; J Reviriego
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

5.  Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam.

Authors:  D J Greenblatt; M K Divoll; M H Soong; H G Boxenbaum; J S Harmatz; R I Shader
Journal:  J Clin Pharmacol       Date:  1988-09       Impact factor: 3.126

6.  Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation.

Authors:  T Inaba; A Tait; M Nakano; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1988 Jul-Aug       Impact factor: 3.922

7.  Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450.

Authors:  M E McManus; W M Burgess; M E Veronese; A Huggett; L C Quattrochi; R H Tukey
Journal:  Cancer Res       Date:  1990-06-01       Impact factor: 12.701

8.  Characterisation of theophylline metabolism in human liver microsomes.

Authors:  R A Robson; A P Matthews; J O Miners; M E McManus; U A Meyer; P M Hall; D J Birkett
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

9.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes.

Authors:  S Yamano; J Tatsuno; F J Gonzalez
Journal:  Biochemistry       Date:  1990-02-06       Impact factor: 3.162

10.  Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

Authors:  L Bertilsson; T K Henthorn; E Sanz; G Tybring; J Säwe; T Villén
Journal:  Clin Pharmacol Ther       Date:  1989-04       Impact factor: 6.875

View more
  43 in total

1.  Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.

Authors:  Z H Xu; W Wang; X J Zhao; S L Huang; B Zhu; N He; Y Shu; Z Q Liu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

3.  To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.

Authors:  Sieto Bosgra; Maria L H Vlaming; Wouter H J Vaes
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 4.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

5.  Voriconazole and fluconazole increase the exposure to oral diazepam.

Authors:  Teijo I Saari; Kari Laine; Leif Bertilsson; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2007-08-04       Impact factor: 2.953

6.  Maintenance time of sedative effects after an intravenous infusion of diazepam: a guide for endoscopy using diazepam.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Akiko Nakamura; Naohito Shirai; Mutsuhiro Ikuma; Shingen Misaka; Shinya Uchida; Hiroshi Watanabe; Kyoichi Ohashi; Takashi Ishizaki; Akira Hishida
Journal:  World J Gastroenterol       Date:  2008-09-07       Impact factor: 5.742

Review 7.  Classics in chemical neuroscience: diazepam (valium).

Authors:  Nicholas E Calcaterra; James C Barrow
Journal:  ACS Chem Neurosci       Date:  2014-02-27       Impact factor: 4.418

8.  Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.

Authors:  Eva Bredberg; Tommy B Andersson; Lars Frison; Annelie Thuresson; Susanne Johansson; Maria Eriksson-Lepkowska; Marita Larsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 9.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology.

Authors:  L L von Moltke; D J Greenblatt; J Schmider; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.